Scarica l'app Stockscreener
34.73
1.94%
0.66
Dopo l'orario di chiusura:
34.90
0.17
+0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$34.07
Aprire:
$33.85
Volume 24 ore:
6.38M
Relative Volume:
1.10
Capitalizzazione di mercato:
$24.98B
Reddito:
$8.26M
Utile/perdita netta:
$-397.91M
Rapporto P/E:
-68.96
EPS:
-0.5036
Flusso di cassa netto:
$-758.56M
1 W Prestazione:
+11.14%
1M Prestazione:
+15.81%
6M Prestazione:
+60.05%
1 anno Prestazione:
+204.92%
Intervallo 1D:
$33.61
$34.83
Intervallo di 1 settimana:
$30.70
$34.83
Portata 52W:
$10.71
$34.83
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.73 | 24.51B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Defensive Index - marketscreener.com
Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing - Moomoo
Understanding the Setup: (ROIV) and Scalable Risk - Stock Traders Daily
Price to sales forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBITDA forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBIT forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 26 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Roivant Sciences(ROIV.US) Officer Sells US$6.63 Million in Common Stock - Moomoo
Roivant (NASDAQ: ROIV) president sells 200K shares, exercises 200K stock options - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 25 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 25 June By Investing.com - Investing.com South Africa
Roivant Sciences Ltd (ROIV) Institutional Confidence - TradingKey
JNJ Stock Price and Chart — NYSE:JNJ - TradingView
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Morgan Stanley Smith Barney files 500,000-share sale (NASDAQ: ROIV) - Stock Titan
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study - Benzinga
Roivant Sciences stock hits all-time high at 32.8 USD - Investing.com
Roivant Sciences stock hits all-time high at 32.8 USD By Investing.com - Investing.com Nigeria
Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Roivant Sciences Ltd (ROIV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Roivant Sciences Ltd. (ROIV) Stock Analysis: Navigating Biotech Opportunities with 24.22% Potential Upside - DirectorsTalk Interviews
Roivant Sciences Ltd (ROIV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders - simplywall.st
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress - simplywall.st
Roivant Sciences Ltd (ROIV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Roivant Sciences Ltd (ROIV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fidelity Advisor Biotechnology Fund's Roivant Sciences Ltd(ROIV) Holding History - GuruFocus
Roivant Sciences Ltd (ROIV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Roivant Sciences Ltd (ROIV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
The Technical Signals Behind (ROIV) That Institutions Follow - Stock Traders Daily
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory - Insider Monkey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
12 Best Growth Stocks Trading in Oversold Territory - Insider Monkey
Global Endurance Portfolio's Roivant Sciences Ltd(ROIV) Holding History - GuruFocus
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 29.97% Upside in Biotech Innovation - DirectorsTalk Interviews
Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Guggenheim and Citi Raise Roivant Sciences Price Targets After EarningsEarnings Surprise Score - newsline.com
Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Insider Monkey
ROIV: Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans - TradingView
ROIV: Late-stage pipeline advances in rare diseases and immunology, with strong financial flexibility - TradingView
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):